Valproic acid induces extracellular signal-regulated kinase 1/2 activation and inhibits apoptosis in endothelial cells

Cell Death and Differentiation

Volumn 13, Issue 3, 2006, Pages 446-453

  Michaelis, M ^a   Suhan, T ^a   Michaelis, U R ^a   Beek, K ^a   Rothweiler, F ^a   Tausch, L ^b   Werz, O ^b   Eikel, D ^c   Zornig M ^d   Nau, H ^c   Fleming, I ^a   Doerr, H W ^a   Cinatl Jr , J ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c CENTER FOR SYSTEMS NEUROSCIENCE   (Germany)

^d INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

Author keywords

Angiogenesis; Apoptosis; Endothelial cell; ERK; Valproic acid

Indexed keywords

2 (2 AMINO 3 METHOXYPHENYL)CHROMONE; ANGIOGENESIS INHIBITOR; CYTOCHROME C; HISTONE DEACETYLASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; PROTEIN BCL 2; VALPROIC ACID; VALPROIC ACID DERIVATIVE;

ANGIOGENESIS; APOPTOSIS; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG POTENTIATION; ENDOTHELIUM CELL; ENZYME ACTIVATION; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; PRIORITY JOURNAL; PROTEIN SECRETION; SIGNAL TRANSDUCTION; UMBILICAL VEIN; VASCULAR ENDOTHELIUM;

ANGIOGENESIS INHIBITORS; ANIMALS; APOPTOSIS; CELL CYCLE; CELLS, CULTURED; CHICK EMBRYO; DRUG SYNERGISM; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; ENZYME ACTIVATION; ENZYME INHIBITORS; FLAVONOIDS; HUMANS; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASE KINASES; PHOSPHORYLATION; VALPROIC ACID;

EID: 33645134544     PISSN: 13509047     EISSN: 14765403     Source Type: Journal    
DOI: 10.1038/sj.cdd.4401759     Document Type: Article

References (40)

1. Perucca E (2002) Pharmacological and therapeutic properties of valproate: A summary after 35 years of clinical experience. CNS Drugs 16: 695-714
2. Citrome L (2003) Schizophrenia and valproate. Psychopharmacol. Bull. 37: 74-8
3. Belmaker RH (2004) Bipolar disorder. N. Engl. J. Med. 351: 476-486
4. Frediani F (2004) Anticonvulsant drugs in primary headaches prophylaxis. Neurol. Sci. 25: S161-S166
5. Blaheta RA, Michaelis M, Hernáiz Driever P and Cinatl Jr J (2005) The evolving anticancer drug valproic acid: Insights into the mechanism and clinical studies. Med. Res. Rev. 2005 [Epub ahead of print]
6. Nau H, Hauck RS and Ehlers K (1991) Valproic acid-induced neural tube defects in the mouse and human: Aspects of chirality, alternative drug development, pharmacokinetics and possible mechanisms. Pharmacol. Toxicol. 69: 310-321
7. Nau H (1994) Valproic acid-induced neural tube defects. Ciba Found. Symp. 181: 144-152
8. Sonoda T, Ohdo S, Ohba K, Okishima T and Hayakawa K (1993) Sodium valproate-induced cardiovascular abnormalities in the Jcl:ICR mouse fetus: Peak sensitivity of gestational day and dose-dependent effect. Teratology 48: 127-132
9. Thisted E and Ebbesen F (1993) Malformations, withdrawal manifestations, and hypoglycaemia after exposure to valproate in utero. Arch. Dis. Child. 69: 288-291
10. Andrews JE, Ebron-McCoy MT, Bojic U, Nau H and Kavlock RJ (1997) Stereoselective dysmorphogenicity of the enantiomers of the valproic acid analogue 2-N-propyl-4-pentynoic acid (4-yn-VPA): Cross-species evaluation in whole embryo culture. Teratology 55: 314-318
11. Michaelis M, Michaelis UR, Fleming I, Suhan T, Cinatl J, Blaheta RA, Hoffmann K, Kotchetkov R, Busse R, Nau H and Cinatl Jr J (2004) Valproic acid inhibits angiogenesis in vitro and in vivo. Mol. Pharmacol. 65: 520-527
12. Rössig L, Li H, Fisslthaler B, Urbich C, Fleming I, Forstermann U, Zeiher AM and Dimmeler S (2002) Inhibitors of histone deacetylation downregulate the expression of endothelial nitric oxide synthase and compromise endothelial cell function in vasorelaxation and angiogenesis. Circ. Res. 91: 837-844
13. Phiel CJ, Zhang F, Huang EY, Guenther MG, Lazar MA and Klein PS (2001) Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J. Biol. Chem. 276: 36734-36741
14. Göttlicher M, Minucci S, Zhu P, Krämer OH, Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, Pelicci PG and Heinzel T (2002) Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J. 20: 6969-6978
15. Gurvich N, Tsygankova OM, Meinkoth JL and Klein PS (2004) Histone deacetylase is a target of valproic acid-mediated cellular differentiation. Cancer Res. 64: 1079-1086
16. Villar-Garea A and Esteller M (2004) Histone deacetylase inhibitors: understanding a new wave of anticancer agents. Int. J. Cancer 112: 171-178
17. Johnstone RW (2002) Histone-deacetylase inhibitors: Novel drugs for the treatment of cancer. Nat. Rev. Drug Discov. 1: 287-299
18. Brunello N (2004) Mood stabilizers: Protecting the mood... protecting the brain. J. Affect. Disord. 79: S15-S20
19. Facchetti F, Previdi S, Ballarini M, Minucci S, Perego P and La Porta CA (2004) Modulation of pro- and antiapoptotic factors in human melanoma cells exposed to histone deacetylase inhibitors. Apoptosis 9: 573-582
20. Yuan PX, Huang LD, Jiang YM, Gutkind JS, Manji HK and Chen G (2001) The mood stabilizer valproic acid activates mitogen-activated protein kinases and promotes neurite growth. J. Biol. Chem, 276: 31674-31683
21. Chang F, Steelman LS, Shelton JG, Lee JT, Navolanic PM, Blalock WL, Franklin R and McCubrey JA (2003) Regulation of cell cycle progression and apoptosis by the Ras/Raf/MEK/ERK pathway. Int. J. Oncol. 22: 469-180
22. Karsan A, Yee E, Poirier GG, Zhou P, Craig R and Harlan JM (1997) Fibroblast growth factor-2 inhibits endothelial cell apoptosis by Bcl-2-dependent and independent mechanisms. Am. J. Pathol. 151: 1775-1784
23. Liu W, Ahmed SA, Reinmuth N, Shaheen RM, Jung YD, Fan F and Ellis LM (2000) Endothelial cell survival and apoptosis in the tumor vasculature. Apoptosis 5: 323-328
24. Zachary I (2003) VEGF signalling: Integration and multi-tasking in endothelial cell biology. Biochem. Soc. Trans. 31: 1171-1177
25. Graaf MR, Richel DJ, van Noorden CJ and Guchelaar HJ (2004) Effects of statins and famesyltransferase inhibitors on the development and progression of cancer. Cancer Treat. Rev. 30: 609-641
26. Hara M, Akasaka K, Akinaga S, Okabe M, Nakano H, Gomez R, Wood D, Uh M and Tamanoi F (1993) Identification of Ras famesyltransferase inhibitors by microbial screening. Proc. Natl. Acad. Sci. USA 90: 2281-2285
27. Sebolt-Leopold JS and Herrera R (2004) Targeting the mitogen-activated protein kinase cascade to treat cancer. Nat. Rev. Cancer 4: 937-947
28. Gerber HP, Dixit V and Ferrara N (1998) Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J. Biol. Chem. 273: 13313-13316
29. Yang Y and Yu X (2003) Regulation of apoptosis: The ubiquitous way. FASEB J. 17: 790-799
30. Bürkert E, Szellas D, Radmark O, Steinhilber D and Werz O (2003) Cell type-dependent activation of 5-lipoxygenase by arachidonic acid. J. Leukoc. Biol. 73: 191-200
31. Marinissen MJ and Gutkind JS (2001) G-protein-coupled receptors and signaling networks: Emerging paradigms. Trends Pharmacol. Sci. 22: 368-376
32. Dias N and Bailly C (2005) Drugs targeting mitochondrial functions to control tumor cell growth. Biochem. Pharmacol. [Epub ahead of print]
33. De Felice L, Tatarelli C, Mascolo MG, Gregorj C, Agostini F, Fiorini R, Gelmetti V, Pascale S, Padula F, Petrucci MT, Arcese W and Nervi C (2005) Histone deacetylase inhibitor valproic acid enhances the cytokine-induced expansion of human hematopoietic stem cells. Cancer Res. 65: 1505-1513
34. Goodwin FK, Fireman B, Simon GE, Hunkeler EM, Lee J and Revicki D (2003) Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA 290: 1467-1473
35. Bojic U, Ehlers K, Ellerbeck U, Bacon CL, O'Driscoll E, O'Connell C, Berezin V, Kawa A, Lepekhin E, Bock E, Regan CM and Nau H (1998) Studies on the teratogen pharmacophore of valproic acid analogues: Evidence of interactions at a hydrophobic centre. Eur. J. Pharmacol. 354: 289-299
36. Gravemann U (2002) synthesis of achiral, racemic and enantiomerically pure valproic acid derivatives with anticonvulsant, neurotoxic and teratogenic potency. Thesis, University of Hannover
37. Michaelis M, Suhan T, Cinatl J, Hernáiz Driever P and Cinatl Jr J (2004) Valproic acid and interferon-alpha synergistically inhibit neuroblastoma cell growth in vitro and in vivo. Int. J. Oncol. 25: 1795-1799
38. Waterhouse NJ and Trapani JA (2003) A new quantitative assay for cytochrome c release in apoptotic cells. Cell Death Differ. 10: 853-855
39. Werz O, Bürkert E, Samuelsson B, Radmark O and Steinhilber D (2002) Activation of 5-lipoxygenase by cell stress is calcium independent in human polymorphonuclear leukocytes. Blood 99: 1044-1052
40. 2+ indicators with greatly improved fluorescence properties. J. Biol. Chem. 260: 3440-3450